Dublin, Aug. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Antidiabetic Drug Market (2021-2026) by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.
The major factors such as Unhealthy food habits among individuals of all ages, increase in the prevalence of diabetes (both type I and type II), increase in obesity among people are driving the rise of the anti-diabetic drug market. Furthermore, the rising elderly population is a major driver of market expansion.
According to the International Diabetes Foundation, diabetes affects one in every five persons aged 65 and up throughout the world. In addition, growing government spending and health-awareness efforts to successfully treat diabetes, as well as investments in research and development and the invention of different techniques to control diabetes and create sophisticated anti-diabetic drugs, as per the growing requirement is expected to create opportunities for the market growth.
However, an important factor restraining the antidiabetics drug market is the decrease in treatment and drug efficacy over time, which can lead to various health issues. In addition, the high cost of medicines is seen as a challenge for the growth of the global antidiabetic drug market.
By Drug Type, the market is classified into A-Glucosidase Inhibitors (Acarbose), Biguanides (Metformin), Dipeptidyl Peptidase IV (DPP-IV) Inhibitors (Sitagliptin), Meglitinides (Repaglinide), Sulfonylureas (Glimepiride), Thiazolidinediones (Pioglitazone), and others. Amongst all, the A-Glucosidase Inhibitors (Acarbose), segment is estimated to hold the highest market share during the forecast period.
By Diabetic Type, the market is classified as diabetes type 1 and diabetes type 2. Amongst all, the diabetes type 1 segment is estimated to hold the highest market share during the forecast period.
By Patient, the market is classified as adult, geriatric, and paediatric. Amongst all, the adult segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Mankind Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd inked a sub-licensing agreement to co-market anti-diabetes drug remogliflozin etabonate in India. - 23rd December 2019
Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone Lispro Formulation Containing - 25th January 2021
Some of the companies covered in this report are
Merck & Co. Inc.
Key Topics Covered:
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1.1 Sedentary Lifestyle of People and Irregular Dietary Habits
4.1.2 Growing Awareness Amongst People of Antidiabetics Drugs
4.1.3 Government Initiatives in Healthcare Sector
4.2.1 Excessive Cost of Insulin
4.3.1 New Innovation in Medical Devices Relate to Diabetics
4.3.2 Increased Investment in R&D
4.4.1 Safety Concerns Relating to Some Diabetic Drugs
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Antidiabetic Drug Market, By Drug Type
6.2 A-Glucosidase Inhibitors (Acarbose)
6.3 Biguanides (Metformin)
6.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors (Sitagliptin)
6.5 Meglitinides (Repaglinide)
6.6 Sulfonylureas (Glimepiride)
6.7 Thiazolidinediones (Pioglitazone)
7 Global Antidiabetic Drug Market, By Diabetes Type
7.2 Diabetes Type 1
7.3 Diabetes Type 2
8 Global Antidiabetic Drug Market, By Patient
9 Global Antidiabetic Drug Market, By Geography
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Strategic Initiatives
11 Company Profiles
Aristo Pharmaceuticals Pvt. Ltd
Astellas Pharma Inc
Biocon Limited C.H.
Boehringer Sohn AG & Co.
KG Cadila Pharmaceuticals Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Glenmark Pharmaceuticals Ltd
Halozyme Therapeutics, Inc
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mankind Pharma Ltd
Novo Nordisk A/S
Oramed Pharmaceuticals Inc
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd
Tonghua Dongbao Pharmaceutical Co, Ltd
For more information about this report visit https://www.researchandmarkets.com/r/9orziw
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900